This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Swiatlo, E. Articles by Briles, D. E. Search for Related Content PubMed PubMed Citation Articles by Swiatlo, E. Articles by Briles, D. E.

 Previous Article  |  Next Article 

Infection and Immunity, December 2003, p. 7149-7153, Vol. 71, No. 12
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.12.7149-7153.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Pneumococcal Surface Protein A Is Expressed In Vivo, and Antibodies to PspA Are Effective for Therapy in a Murine Model of Pneumococcal Sepsis

E. Swiatlo,^1* J. King,² G. S. Nabors,^3, B. Mathews,² and D. E. Briles^2,4

Departments of Medicine,¹ Microbiology,² Comparative Medicine, University of Alabama at Birmingham, Birmingham, Alabama,⁴ Aventis Inc., Swiftwater, Pennsylvania³

Received 15 May 2003/ Returned for modification 3 July 2003/ Accepted 3 September 2003

Pneumococcal surface protein A (PspA) is an immunogenic protein expressed on the surface of all strains of Streptococcus pneumoniae (pneumococcus) and induces antibodies which protect against invasive infection in mice. Pneumococci used for infectious challenge in protection studies are typically collected from cultures grown in semisynthetic medium in vitro. The purpose of these studies is to confirm that PspA is expressed by pneumococci during growth in vivo at a level sufficient for antibodies to PspA to be protective. Mice were actively immunized with purified PspA or by passive transfer of monoclonal antibody (MAb) and challenged with a capsular type 3 strain in diluted whole blood from bacteremic mice. All were protected against challenge with 10 times the 50% lethal dose (LD₅₀), and mice challenged with 1,000 times the LD₅₀ had increased survival compared with controls. Additionally, nonimmune mice treated with MAbs to PspA or PspA immune serum at 6 and 12 h after infection with 10 times the LD₅₀ also showed increased survival. Northern blot analysis of RNA from pneumococci grown either in vitro or in vivo showed similar levels of PspA mRNA. These results demonstrate that PspA is expressed in vivo in a mouse model and that immunization with PspA induces antibodies to an antigen which is expressed during the course of invasive infection. Immunotherapy with antibodies to PspA may have some utility in treating pneumococcal infections in humans.

Editor: J. N. Weiser

Present address: Antex Biologics, Inc., Gaithersburg, Md.

This article has been cited by other articles:

• Ogunniyi, A. D., Grabowicz, M., Briles, D. E., Cook, J., Paton, J. C. (2007). Development of a Vaccine against Invasive Pneumococcal Disease Based on Combinations of Virulence Proteins of Streptococcus pneumoniae. Infect. Immun. 75: 350-357 [Abstract] [Full Text]  
• Briles, D. E., Novak, L., Hotomi, M., van Ginkel, F. W., King, J. (2005). Nasal Colonization with Streptococcus pneumoniae Includes Subpopulations of Surface and Invasive Pneumococci. Infect. Immun. 73: 6945-6951 [Abstract] [Full Text]  
• Areas, A. P. M., Oliveira, M. L. S., Miyaji, E. N., Leite, L. C. C., Ho, P. L. (2005). Intradermal Immunization of Mice with Cholera Toxin B-Pneumococcal Surface Protein A Fusion Protein Is Protective against Intraperitoneal Challenge with Streptococcus pneumoniae. Infect. Immun. 73: 3810-3813 [Full Text]  
• Oggioni, M. R., Iannelli, F., Ricci, S., Chiavolini, D., Parigi, R., Trappetti, C., Claverys, J.-P., Pozzi, G. (2004). Antibacterial Activity of a Competence-Stimulating Peptide in Experimental Sepsis Caused by Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 4725-4732 [Abstract] [Full Text]